J&J Zarnestra R&D Overseen By Ortho Oncology/HIV Group, Headed By Mattes

Clinical development of Johnson & Johnson's farnesyl transferase inhibitor Zarnestra will be overseen by the company's tentatively named Ortho Oncology & Specialty Therapeutics business unit